Filing Analysis
Enzon Pharmaceuticals announced a dividend payment for its Series C Non-Convertible Redeemable Preferred Stock. The 3% cash dividend will be paid on January 9, 2025.
🚩 Red Flags
- Preferred stock dividends can sometimes indicate a priority claim on assets over common shareholders in liquidation scenarios.
📋 Key Facts
- Dividend rate: 3% cash dividend on Series C Preferred Stock.
- Aggregate dividend amount: $1,274,400.
- Per share dividend amount: $31.86 per share of Series C Preferred Stock.
- Total shares subject to dividend: 40,000 outstanding shares of Series C Preferred Stock.
- Record date: January 2, 2025.
- Payment date: January 9, 2025.
Enzon Pharmaceuticals held its 2024 annual meeting of stockholders on September 26, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, executive compensation, and an amendment to a Rights Agreement.
📋 Key Facts
- Annual Meeting held on September 26, 2024.
- Quorum was present with 58,112,406 shares (approx. 78% of total shares) represented.
- Three directors elected: Jordan Bleznick, Jaffery (Jay) A. Firestone, and Randolph C. Read.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Shareholders approved an amendment to the Rights Agreement with Continental Stock Transfer & Trust Company, extending the Final Expiration Date to March 31, 2025.
This 8-K/A is an amendment to a previous filing intended solely to clarify the record date for Enzon Pharmaceuticals' 2024 Annual Meeting of Stockholders. The company has set the meeting date for September 26, 2024.
📋 Key Facts
- Annual Meeting Date: September 26, 2024
- Record Date: August 7, 2024
- Deadline for stockholder proposals/nominations: July 12, 2024
- Filing is an amendment (8-K/A) to clarify the record date previously disclosed.
Enzon Pharmaceuticals announced the scheduling of its 2024 Annual Meeting of Stockholders. The meeting is set for September 26, 2024, with a record date of August 13, 2024.
📋 Key Facts
- Annual Meeting Date: September 26, 2024
- Record Date: August 13, 2024
- Deadline for stockholder proposals/nominations: July 12, 2024
- The filing provides notice due to the meeting being held more than 25 days after June 8, 2024.
Enzon Pharmaceuticals has regained compliance with OTCQX listing standards after meeting the minimum bid price requirement of $0.10 per share. The company is currently in full compliance and no further remedial action is required at this time.
🚩 Red Flags
- History of delisting risk/non-compliance (notified in January 2024).
📋 Key Facts
- The Company was notified by OTCQX on June 10, 2024, that it has regained compliance with continued qualification standards.
- Compliance was achieved because the stock price traded at or above $0.10 for the required period.
- The company had previously been non-compliant since January 2024 regarding the minimum bid price requirement.
- The deadline to regain compliance was July 15, 2024.
Enzon Pharmaceuticals entered into a Second Amendment to its Section 382 Rights Agreement on May 16, 2024. The amendment extends the Final Expiration Date of the rights from June 2, 2024, to March 31, 2025.
🚩 Red Flags
- Repeated extensions of rights expiration dates may indicate ongoing efforts to manage ownership thresholds or prevent changes in control/tax implications related to Section 382.
📋 Key Facts
- The Second Amendment was entered into with Continental Stock Transfer & Trust Company as rights agent on May 16, 2024.
- The amendment extends the Final Expiration Date of the rights from June 2, 2024, to March 31, 2025.
- All other terms of the original Rights Agreement (dated August 14, 2020) and the First Amendment remain unmodified.
Enzon Pharmaceuticals announced a dividend payment for its Series C Non-Convertible Redeemable Preferred Stock. The dividend is 3% of the par value, totaling $1,274,400.
🚩 Red Flags
- The dividend is paid to preferred shareholders (Series C), which may represent a priority claim on cash before common shareholders.
📋 Key Facts
- Dividend amount: $1,274,400 in aggregate ($31.86 per share).
- Dividend rate: 3% cash dividend on Series C Preferred Stock.
- Shares affected: 40,000 outstanding shares of Series C Non-Convertible Redeemable Preferred Stock.
- Record date: January 10, 2024.
- Payment date: January 17, 2024.